WEBULL
WebtradeDownload

Ultragenyx Pharmaceutical (RARE) Shares Moved, What Is Catching Investors' Attention?

Simply Wall St · 1d ago

Ultragenyx Pharmaceutical (RARE) is back in focus after UK regulators granted conditional marketing authorisation for its rare disease drug Dojolvi, creating a fresh talking point for the stock beyond recent earnings.

Ultragenyx Pharmaceutical’s share price has been under pressure over the past year, with a year-to-date share price return of down 29.53% and a 1-year total shareholder return of down 48.77%. However, the 30-day share price return of 9.26% and the 1-day move of 2.02% suggest some momentum has started to reappear as investors weigh the improved third quarter loss figures alongside the fresh UK approval for Dojolvi.

Scan how Ultragenyx Pharmaceutical compares with other rare-disease and high-cash-flow biopharma plays that could be primed for a similar rerating by checking the curated 19 high quality undiscovered gems in this space.

Ultragenyx Pharmaceutical has a share price near US$16.63 while analyst targets and intrinsic value estimates sit meaningfully higher, especially after the Dojolvi decision. How wide is the gap between price and fair value now?

Most Popular Narrative: 36% Undervalued

On the numbers alone, the gap is stark. Ultragenyx Pharmaceutical last closed at $16.63, while the most followed valuation narrative pegs fair value around $26, implying meaningful upside from here based on that framework.

The "Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.

Here is why the market is mispricing the friction inside RARE’s operational engine:

See why 2 investors see Ultragenyx Pharmaceutical as 36% undervalued.

According to AnimalDoctorKwon, the key issue is not whether Ultragenyx Pharmaceutical has strong science or multiple approved rare-disease therapies. The focus is on whether the rare-disease commercial model, royalty structure and upcoming gene-therapy investment needs can realistically support a move from a current net loss of $586.0m on $717.0m in revenue to the margins implied by a fair value around $26 per share.

The same thesis points to several structural frictions that sit behind that valuation view. These include high selling costs to reach small patient pools, royalty and co-promotion splits that limit how much Crysvita economics reach the parent company, and future manufacturing costs tied to late-stage gene-therapy candidates such as DTX401 and UX701.

Forecast data in the statements gives some support to the idea that the future picture may look different to today. Earnings are projected to grow 77.08% per year and the business is expected to become profitable within 3 years, with a forecast return on equity of 27.4% and revenue growth of 18% per year, which is above the wider US market expectation of 13.1% per year.

At the same time, risk flags in the data show why the narrative stresses a thin margin for error. Ultragenyx Pharmaceutical is unprofitable, has recorded rising losses over 5 years, carries negative shareholders’ equity and is assessed as having less than 1 year of cash runway, with 100% of liabilities funded from higher-risk sources rather than deposits.

Market pricing today embeds that mix of potential and pressure. Analysts see a target around $26.25 per share and Simply Wall St’s own model marks the stock as trading 91.2% below an internal fair value estimate and below an assessed future cash flow value of $188.60, although analyst targets are described as dispersed and not tightly clustered.

Put together, the most popular narrative argues that the science and late-stage pipeline can support a higher valuation, yet the current structure of costs, funding and capital intensity must bend in Ultragenyx Pharmaceutical’s favor for that to play out.

Result: Fair Value of $26 (UNDERVALUED)

Still, Ultragenyx Pharmaceutical could quickly challenge this underpriced story if royalty economics improve faster than expected or if planned gene therapy spending ends up below current market fears.

Find out about the key risks to this Ultragenyx Pharmaceutical narrative.

Next Steps

Sentiment around Ultragenyx Pharmaceutical is clearly mixed, with sharp risks on one side and meaningful potential on the other. Move quickly and interrogate the underlying data yourself, then size up both sides of the story with the 2 key rewards and 3 important warning signs.

Looking for more Ultragenyx Pharmaceutical style investment ideas?

Do not stop with Ultragenyx Pharmaceutical. Use the Simply Wall St screener to quickly spot other opportunities that fit your risk, income, and value goals before they move.